Cilag GmbH International — an affiliate of Johnson & Johnson Diabetes Care’s LifeScan — has entered into strategic collaboration agreement with WellDoc to advance mobile solutions that provide Type 2 diabetes patients with real time data to improve their health outcomes. In addition, Johnson & Johnson Innovation – JJDC (JJDC) has also invested in WellDoc, helping bring the company’s Series B round of funding to $29.5 million — up from $22 million when it was originally announced in December 2015.

“This exciting collaboration bridges our strong history serving diabetes patients and their healthcare team with WellDoc’s innovative diabetes management platform that has been shown to improve health outcomes. By working together, we look forward to advancing new solutions,” Val Asbury, World Wide President of LifeScan, said in a statement.

Under the deal, the two companies will work to integrate LifeScan’s newly launched Bluetooth-enabled, OneTouch Verio Flex blood glucose monitoring system and OneTouch Reveal mobile app with WellDoc’s BlueStar diabetes management platform and mobile app, the first mobile prescription therapy approved by the FDA for Type 2 diabetes. OneTouch Verio Flex features ColorSure technology, which is an easy-to-use meter that takes the guesswork out of understanding blood sugar test results for people with diabetes. The integration would provide patients additional smart monitoring tools and real-time motivational, behavioral and educational coaching, which clinical studies have shown improve patient health.

In a clinical trial, WellDoc showed that when patients used its diabetes management platform for a 12-month period they had a 1.9 percent decline in glycated hemoglobin level over 12 months compared with a 0.7 percent decrease in the usual care group.